SIO CAPITAL MANAGEMENT LLC
Q1 2024 Form 13-F

NEW YORK, NEW YORK
CIK 0001482416 · CRD 165989 · SEC-registered investment adviser
$335.8M Reported Value Total

SIO CAPITAL MANAGEMENT, LLC reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $1,405,889,917, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
6 funds · $864.7M gross asset value
Hedge Fund: $864.7M
Source: Form ADV filed 2026-03-18
Reported value
$335.8M
Quarter over quarter
+14.2%
Holdings
48
Top-10 concentration
58.6%

Key People

Form ADV owners & control persons
Michael Bernard Castor
MANAGING MEMBER
Judah Zvi Drillick
CHIEF EXECUTIVE OFFICER
Jin Woo Lee
CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2024 13F record

Q1 2024 13F filing summary

Q1 2024 Form 13F portfolio summary
Period of report March 31, 2024
Filed May 15, 2024
Form 13F-HR
Reported value $335.8M
Positions 48
Change in reported value -23.5%
New positions 21
Exited positions 12
Position turnover 55.0%
Top-10 concentration 58.6%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
51 $528.5M
Q2 2026 13F
Filed Aug 14, 2026
57 $604.3M
Q1 2026 13F
Filed May 14, 2026
73 $697.3M
Q4 2025 13F
Filed Feb 17, 2026
65 $635.7M
Q3 2025 13F
Filed Nov 13, 2025
51 $395.2M
Q2 2025 13F
Filed Aug 13, 2025
49 $261.8M
Q1 2025 13F
Filed May 15, 2025
53 $335.8M
Q4 2024 13F
Filed Feb 14, 2025
51 $355.4M
Q3 2024 13F
Filed Nov 14, 2024
38 $252.2M
Q2 2024 13F
Filed Aug 14, 2024
46 $369.5M
Q1 2024 13F
Filed May 15, 2024
48 $335.8M
Q4 2023 13F
Filed Feb 13, 2024
39 $439.2M
Q3 2023 13F
Filed Nov 14, 2023
52 $323.1M
Q2 2023 13F
Filed Aug 14, 2023
41 $393.2M
Q1 2023 13F
Filed May 12, 2023
44 $202.3M
Q4 2022 13F
Filed Feb 13, 2023
41 $270.4M
Q3 2022 13F
Filed Nov 14, 2022
43 $314.7M
Q2 2022 13F
Filed Aug 15, 2022
59 $266.2M
Q1 2022 13F
Filed May 16, 2022
61 $302.3M
Q4 2021 13F
Filed Feb 14, 2022
67 $331.7M

28 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q1 2024

Largest Q1 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 LH LABORATORY CORPORATION OF AMERICA HOLDINGS $49.4M 14.69%
2 INSM P INSMED INC $37.0M 11.01%
3 CI CIGNA GROUP $27.6M 8.23%
4 GMED GLOBUS MEDICAL INC $21.1M 6.28%
5 MDGL MADRIGAL PHARMACEUTICALS INC $13.6M 4.06%
6 GSK GSK PLC $11.3M 3.36%
7 ZBH ZIMMER BIOMET HOLDINGS INC $9.8M 2.92%
8 MDT MEDTRONIC PLC $9.2M 2.72%
9 OGN ORGANON & CO $9.0M 2.68%
10 TYRA TYRA BIOSCIENCES INC $8.8M 2.62%
11 IRWD P IRONWOOD PHARMACEUTICALS INC $8.5M 2.52%
12 EMBC EMBECTA CORP $7.8M 2.31%
13 TFX TELEFLEX INCORPORATED $7.7M 2.28%
14 ARQT ARCUTIS BIOTHERAPEUTICS INC $6.3M 1.88%
15 BBIO BRIDGEBIO PHARMA INC $6.3M 1.87%
16 HUMA HUMACYTE INC $6.2M 1.85%
17 ANIP ANI PHARMACEUTICALS INC $6.0M 1.8%
18 ATXS ASTRIA THERAPEUTICS INC $5.8M 1.72%
19 SPRY ARS PHARMACEUTICALS INC $5.5M 1.63%
20 HCSG HEALTHCARE SERVICES GROUP INC $5.3M 1.57%

Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings